Innoviva, Inc.'s Form 4 filing
Armata Pharmaceuticals, Inc. (ARMP) · filed Apr 1, 2022
- Accession no.
- 0001567619-22-007861
- Filed
- Apr 1, 2022, 4:52 PM ET
- Trade date
- Mar 31, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $26.9M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Innoviva, Inc.CIK 0001080014 | Director, 10% Owner |
| Innoviva Strategic Opportunities LLCCIK 0001842875 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Stock | PPurchaseAcquired | +5,385,208 | $5.00 | +$26,926,040 | 16,365,969 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Common Stock | PPurchaseAcquired | +2,692,604 | $5.00 | $0 | 2,692,604 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.